Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 40
Filter
2.
Braz. j. med. biol. res ; 44(7): 660-665, July 2011. ilus, tab
Article in English | LILACS | ID: lil-595706

ABSTRACT

We evaluated the outcome of 227 patients with acute myeloid leukemia during three decades (period 1 - 1980’s, N = 89; period 2 - 1990’s, N = 73; period 3 - 2000’s, N = 65) at a single institution. Major differences between the three groups included a higher median age, rates of multilineage dysplasia and co-morbidities, and a lower rate of clinical manifestations of advanced leukemia in recent years. The proportion of patients who received induction remission chemotherapy was 66, 75, and 85 percent for periods 1, 2, and 3, respectively (P = 0.04). The median survival was 40, 77, and 112 days, and the 5-year overall survival was 7, 13, and 22 percent, respectively (P = 0.01). The median disease-free survival was 266, 278, and 386 days (P = 0.049). Survival expectation for patients with acute myeloid leukemia has substantially improved during this 30-year period, due to a combination of lower tumor burden and a more efficient use of chemotherapy and supportive care.


Subject(s)
Adolescent , Adult , Aged , Aged, 80 and over , Child , Female , Humans , Male , Middle Aged , Young Adult , Hospitalization/statistics & numerical data , Leukemia, Myeloid, Acute/therapy , Brazil/epidemiology , Disease-Free Survival , Induction Chemotherapy/methods , Leukemia, Myeloid, Acute/mortality , Leukemia, Myeloid, Acute/pathology , Prognosis , Retrospective Studies , Survival Rate , Treatment Outcome
3.
Braz J Med Biol Res ; 44(7): 660-5, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21584439

ABSTRACT

We evaluated the outcome of 227 patients with acute myeloid leukemia during three decades (period 1 - 1980's, N = 89; period 2 - 1990's, N = 73; period 3 - 2000's, N = 65) at a single institution. Major differences between the three groups included a higher median age, rates of multilineage dysplasia and co-morbidities, and a lower rate of clinical manifestations of advanced leukemia in recent years. The proportion of patients who received induction remission chemotherapy was 66, 75, and 85% for periods 1, 2, and 3, respectively (P = 0.04). The median survival was 40, 77, and 112 days, and the 5-year overall survival was 7, 13, and 22%, respectively (P = 0.01). The median disease-free survival was 266, 278, and 386 days (P = 0.049). Survival expectation for patients with acute myeloid leukemia has substantially improved during this 30-year period, due to a combination of lower tumor burden and a more efficient use of chemotherapy and supportive care.


Subject(s)
Hospitalization/statistics & numerical data , Leukemia, Myeloid, Acute/therapy , Adolescent , Adult , Aged , Aged, 80 and over , Brazil/epidemiology , Child , Disease-Free Survival , Female , Humans , Induction Chemotherapy/methods , Leukemia, Myeloid, Acute/mortality , Leukemia, Myeloid, Acute/pathology , Male , Middle Aged , Prognosis , Retrospective Studies , Survival Rate , Treatment Outcome , Young Adult
4.
Minerva Stomatol ; 56(7-8): 405-9, 2007.
Article in English | MEDLINE | ID: mdl-17912199

ABSTRACT

Eosinophilic granuloma is classified as a Langerhans cell histiocytosis. Although considered a rare pathology, up to 20% of all cases occur in the jaw bones, and radiographically may mimic odontogenic cysts or benign and malignant tumours. Different protocols have been suggested in the literature for treating eosinophilic granuloma. We report a case of polyostotic eosinophilic granuloma in a 34-year-old man showing ill defined mandibular and palatal radiolucencies. Due to the presence of multiple jaw lesions the treatment choice was chemotherapy. The clinical and radiographic feature are described, as well as treatment, complications and patient's follow-up.


Subject(s)
Eosinophilic Granuloma/drug therapy , Jaw Diseases/drug therapy , Adult , Drug Therapy, Combination , Eosinophilic Granuloma/diagnosis , Humans , Jaw Diseases/diagnosis , Male
5.
Histopathology ; 46(3): 328-33, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15720419

ABSTRACT

AIMS: Diffuse large B-cell lymphoma (DLBCL) is characterized by marked biological heterogeneity. The identification of reproducible parameters that can be combined with the International Prognostic Index (IPI) to better predict outcome could lead to the development of effective risk-adaptive strategies. METHODS AND RESULTS: Bcl-2 and CD10 expression was determined by immunohistochemistry. The impact of the positivity on survival was evaluated in combination with the IPI in 86 patients with a confirmed diagnosis of DLBCL. Patients were divided according to the IPI into low-risk (no to two factors) or high-risk (three to five factors) groups. Positivity rates were 25% for CD10 and 42% for Bcl-2. In a Cox analysis, the high-risk IPI group [hazard ratio (HR) 5.98, P < 0.0001) and Bcl-2 expression (HR 2.43, P = 0.02) were independent poor prognostic factors, and expression of CD10 (HR 0.41, P = 0.052) predicted a favourable outcome. Among patients in the low-risk IPI group, CD10 positivity was associated with an excellent 8-year overall survival (92% versus 45%, P = 0.06). In the high-risk IPI group, Bcl-2 positivity identified a subgroup with invariably fatal disease. CONCLUSIONS: The expression of CD10 in the low-risk IPI group, and the expression of Bcl-2 in the high-risk IPI group can identify two subgroups of patients who might benefit from new risk-adaptive treatment approaches.


Subject(s)
Lymphoma, Large B-Cell, Diffuse/pathology , Neprilysin/biosynthesis , Proto-Oncogene Proteins c-bcl-2/biosynthesis , Adult , Aged , Female , Humans , Immunohistochemistry , Lymphoma, Large B-Cell, Diffuse/classification , Lymphoma, Large B-Cell, Diffuse/metabolism , Male , Middle Aged , Neoplasm Staging , Prognosis , Risk Factors , Survival Analysis
6.
Bone Marrow Transplant ; 31(5): 393-7, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12634731

ABSTRACT

Engraftment syndrome (ES) is an increasingly reported complication of hematopoietic stem cell transplantation (HSCT). In order to better characterize the clinical criteria for the diagnosis of ES, we retrospectively analyzed 125 autologous HSCT recipients. ES was first defined as the presence of noninfectious fever plus skin rash. Patients with and without these findings were compared (univariate and multivariate analyses) regarding the presence of weight gain, hypoalbuminemia, pulmonary infiltrates, diarrhea, neurological manifestations and jaundice. The variables that are significantly more frequent in patients with fever and skin rash were incorporated in the definition criteria. The final diagnostic criteria were noninfectious fever plus any of the following: skin rash, pulmonary infiltrates or diarrhea. The incidence of ES was 20%. The single risk factor for ES by multivariate analysis was a diagnosis other than Hodgkin's disease (odds ratio 6.17, 95% confidence interval 1.38-27.78). Patients with ES received empirical antifungal therapy more frequently than patients without the syndrome (40 vs 19%, P=0.03), and had a longer duration of hospitalization (P=0.0007). The prospective application of these diagnostic criteria may have a favorable impact on the early diagnosis of the syndrome, with the initiation of corticosteroids and a reduction in the unnecessary use of antimicrobial agents.


Subject(s)
Hematopoietic Stem Cell Transplantation/adverse effects , Adolescent , Adult , Aged , Child , Exanthema/etiology , Female , Fever/etiology , Humans , Male , Middle Aged , Retrospective Studies , Risk Factors , Syndrome , Transplantation, Autologous
7.
Am J Trop Med Hyg ; 65(4): 346-50, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11693882

ABSTRACT

The diagnosis of strongyloidiasis relies upon the identification of the parasite in stool samples. In 1981, a serologic assay was developed, which was useful in the diagnosis of strongyloidiasis in the immunocompetent host. In the present study, we evaluated the enzyme-linked immunosorbent assay (ELISA) in patients with hematologic malignancies. Between April 1995 and December 1998, sera from 164 consecutive patients were tested for the presence of IgG antibody to Strongyloides stercoralis. Patient was considered uninfected after at least three negative stool examinations. The prevalence of strongyloidiasis was 13%. The underlying diseases were acute leukemia in 21% and lymphoma in 52% of the patients. The majority of the patients were receiving chemotherapy (93%) and steroids (76%). The sensitivity, specificity, and positive and negative predictive values were 68%, 89%, 48%, and 95%, respectively. The ELISA may be an excellent assay to rule out the diagnosis of strongyloidiasis in patients with hematologic malignancies.


Subject(s)
Hematologic Neoplasms/complications , Immunocompromised Host , Immunoglobulin G/blood , Strongyloides stercoralis/immunology , Strongyloidiasis/diagnosis , Adult , Animals , Antibodies, Helminth/blood , Antigens, Helminth/immunology , Enzyme-Linked Immunosorbent Assay/methods , Feces/parasitology , Female , Hematologic Neoplasms/immunology , Humans , Male , Middle Aged , Predictive Value of Tests , Prevalence , Prospective Studies , Sensitivity and Specificity , Strongyloides stercoralis/isolation & purification , Strongyloidiasis/epidemiology , Strongyloidiasis/etiology , Strongyloidiasis/immunology
8.
Oncol Rep ; 8(3): 693-6, 2001.
Article in English | MEDLINE | ID: mdl-11295104

ABSTRACT

We investigated the presence of free mRNA in the plasma of patients with chronic myeloid leukemia (CML), through RT-PCR analysis of G3PDH, a metabolism gene. We also analysed the presence of mRNA for HLM, a human oxysterol-binding protein homologue recently described as a potential marker for blood dissemination of solid tumors. Our results showed the presence of metabolism G3PDH mRNA in the plasma of 5/11 (45%) CML patients studied but HLM mRNA was not detected in any of the plasma studied. HLM mRNA was detected in the leukocytes of 4/5 (80%) CML patients. This work reports for the first time free mRNA in the plasma of CML patients. Our results also suggest that the detection of HLM could be a potential molecular marker for the follow-up in hematological malignancies.


Subject(s)
Glyceraldehyde-3-Phosphate Dehydrogenases/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , RNA, Messenger/analysis , RNA, Neoplasm/genetics , Receptors, Steroid/genetics , DNA Primers/chemistry , Electrophoresis, Polyacrylamide Gel , Glyceraldehyde-3-Phosphate Dehydrogenases/metabolism , Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood , Leukocytes/metabolism , RNA, Messenger/blood , RNA, Neoplasm/blood , Receptors, Steroid/metabolism , Reverse Transcriptase Polymerase Chain Reaction
9.
Oncol Rep ; 8(2): 441-4, 2001.
Article in English | MEDLINE | ID: mdl-11182071

ABSTRACT

Institutions that treat patients with lymphoma must know their local therapy results and adapt their treatment strategies accordingly. To allow the application of the international prognostic factor index (IPI) in institutions where some of the data necessary are not available, we devised an approach by which the missing data would not impair the applicability of the index. We also collapsed the four categories of the IPI into two categories, and applied this adapted IPI to patients with aggressive non-Hodgkin's lymphoma treated in a public university hospital. Among the 72 patients treated with combination chemotherapy regimens containing doxorubicin, the following outcomes were observed for low and high risk groups, respectively: complete remission rates were 62% and 45% (p=0.2), overall survival rates were 48% and 14% (p=0.0098) and failure-free survival rates were 44% and 17% (p=0.03). This adapted IPI was very effective in predicting the outcome in the patients studied. The survival rates observed in our population were substantially lower than the rates reported in the IPI study. Patient selection might have played an important role in this difference, although other factors related to the social and general health status of the patients treated need to be prospectively studied.


Subject(s)
Lymphoma, Non-Hodgkin/mortality , Lymphoma, Non-Hodgkin/therapy , Adolescent , Adult , Aged , Algorithms , Bone Marrow/pathology , Brazil , Child , Disease-Free Survival , Female , Hospitals, Public , Hospitals, University , Humans , Liver Neoplasms/mortality , Liver Neoplasms/pathology , Liver Neoplasms/therapy , Lymphoma, Non-Hodgkin/pathology , Male , Middle Aged , Neoplasm Staging , Prognosis , Retrospective Studies , Risk Assessment , Splenic Neoplasms/mortality , Splenic Neoplasms/pathology , Splenic Neoplasms/therapy , Survival Rate , Urban Population
10.
Infect Control Hosp Epidemiol ; 22(10): 651-3, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11776354

ABSTRACT

We evaluated the impact of applying the Infectious Diseases Society of America guidelines for febrile neutropenic patients in reducing the use of glycopeptides. Forty-five prior episodes of febrile neutropenia were compared to 97 episodes seen after application of the guidelines. Glycopeptide use was reduced from 73% to 43% of episodes (P=.0008), without changes in outcome.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Drug Therapy, Combination/therapeutic use , Fever/drug therapy , Neutropenia/drug therapy , Practice Guidelines as Topic , Adolescent , Adult , Aged , Amikacin/therapeutic use , Brazil , Cefepime , Ceftazidime/therapeutic use , Cephalosporins/administration & dosage , Child , Female , Fever/complications , Hospitals, Teaching , Humans , Male , Middle Aged , Neutropenia/complications , Oxacillin/administration & dosage , Teicoplanin/therapeutic use , Treatment Outcome , Vancomycin/therapeutic use
11.
Clin Infect Dis ; 31(3): 821-2, 2000 Sep.
Article in English | MEDLINE | ID: mdl-11017840

ABSTRACT

A total of 21 patients with hematologic malignancies were given thiabendazole for treatment of strongyloidiasis. Fifteen patients were cured. Since there were no relapses, it is unlikely that maintenance therapy has a role in the management of strongyloidiasis in this population of patients.


Subject(s)
Antinematodal Agents/therapeutic use , Hematologic Neoplasms/complications , Strongyloidiasis/drug therapy , Thiabendazole/therapeutic use , Adolescent , Adult , Aged , Antinematodal Agents/adverse effects , Child , Dizziness/chemically induced , Female , Follow-Up Studies , Humans , Male , Middle Aged , Patient Compliance , Strongyloidiasis/complications , Thiabendazole/adverse effects , Treatment Outcome
12.
Clin Infect Dis ; 30(2): 300-5, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10671332

ABSTRACT

To evaluate the efficacy of itraconazole capsules in prophylaxis for fungal infections in neutropenic patients, we conducted a prospective, double-blind, placebo-controlled, randomized trial. Patients with hematologic malignancies or those who received autologous bone marrow transplants were assigned either a regimen of itraconazole (100 mg orally twice daily; n=104) or of placebo (n=106). Overall, fungal infections (superficial or systemic) occurred more frequently in the placebo group (15% vs. 6%; P=.03). There were no differences in the empirical use of amphotericin B or systemic fungal infections. Among patients with neutropenia that was profound (<100 neutrophils/mm3) and prolonged (for at least 7 days), those receiving itraconazole used less empirical amphotericin B (22% vs. 61%; P=.0001) and developed fewer systemic fungal infections (6% vs. 19%; P=.04). For patients with profound and prolonged neutropenia, itraconazole capsules at the dosage of 100 mg every 12 h reduce the frequency of systemic fungal infections and the use of empirical amphotericin B.


Subject(s)
Antifungal Agents/administration & dosage , Fungemia/prevention & control , Itraconazole/administration & dosage , Neutropenia/complications , Administration, Oral , Adolescent , Adult , Aged , Amphotericin B/administration & dosage , Aspergillosis/diagnosis , Aspergillosis/etiology , Aspergillosis/mortality , Aspergillosis/prevention & control , Bone Marrow Transplantation , Candidiasis/diagnosis , Candidiasis/etiology , Candidiasis/mortality , Candidiasis/prevention & control , Child , Child, Preschool , Dose-Response Relationship, Drug , Double-Blind Method , Female , Follow-Up Studies , Fungemia/diagnosis , Fungemia/etiology , Fungemia/mortality , Hematologic Neoplasms/complications , Hematologic Neoplasms/therapy , Humans , Male , Middle Aged , Neutropenia/mortality , Prospective Studies , Survival Rate , Transplantation, Autologous , Treatment Outcome
13.
Antimicrob Agents Chemother ; 43(6): 1445-8, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10348768

ABSTRACT

A multicentric randomized trial was undertaken to compare the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in a fat emulsion (Intralipid) in cancer patients. Group 1 (n = 33) received amphotericin B diluted in 5% dextrose with premedication consisting of promethazine plus an antipyretic. Group 2 (n = 28) received amphotericin B diluted in 20% Intralipid without premedication. Amphotericin B was infused daily at a dose of 1 mg/kg of body weight over a 1-h period to members of both groups for empirical antifungal therapy (in neutropenic patients) or for the treatment of documented fungal infections. The majority of patients (80%) received empirical amphotericin B treatment. The two groups were comparable with regard to age, gender, underlying disease, and the following baseline characteristics: use of other nephrotoxic drugs and serum levels of potassium and creatinine. The median cumulative doses of amphotericin B were 240 mg in group 1 and 245 mg in group 2 (P = 0.73). Acute adverse events occurred in 88% of patients in group 1 and in 71% of those in group 2 (P = 0.11). Forty percent of the infusions in group 1 were associated with fever, compared to 23% in group 2 (P < 0.0001). In addition, patients in group 2 required less meperidine for the control of acute adverse events (P = 0.008), and fewer members of this group presented with hypokalemia (P = 0.004) or rigors (P < 0.0001). There was no difference in the proportions of patients with nephrotoxicity (P = 0.44). The success rates of empirical antifungal treatment were similar in the two groups (P = 0.9). Amphotericin B diluted in a lipid emulsion seems to be associated with a smaller number of acute adverse events and fewer cases of hypokalemia than amphotericin B diluted in 5% dextrose.


Subject(s)
Amphotericin B/adverse effects , Fat Emulsions, Intravenous/administration & dosage , Glucose/administration & dosage , Neoplasms/drug therapy , Adolescent , Adult , Aged , Amphotericin B/administration & dosage , Child , Child, Preschool , Female , Humans , Infant , Male , Middle Aged
14.
Diagn Microbiol Infect Dis ; 35(3): 193-6, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10626128

ABSTRACT

To evaluate the value of a positive nasal swab for Aspergillus in the diagnosis of invasive aspergillosis, we prospectively evaluated nasal colonization in 173 episodes of neutropenia in 92 patients with hematological malignancies. Weekly nasal swabs were taken, and the patients were followed until death or resolution of neutropenia. The outcome variables were the development of invasive aspergillosis, empirical antifungal therapy and death. In 31 episodes of neutropenia (18%) there was at least one positive nasal swab for Aspergillus sp. Only two patients developed invasive aspergillosis, both with a positive nasal swab (p = 0.03). The positive and negative predictive values of a nasal swab were 6.4% and 100%, respectively. There was no difference between patients with positive or negative swabs regarding antifungal therapy or death. In this population of patients, a nasal swab for Aspergillus sp. had a low positive predictive value and a high negative predictive value for invasive aspergillosis.


Subject(s)
Aspergillosis/diagnosis , Aspergillus/isolation & purification , Hematologic Neoplasms/complications , Lung Diseases, Fungal/diagnosis , Nasal Cavity/microbiology , Neutropenia/complications , Adolescent , Adult , Aged , Aspergillosis/complications , Aspergillosis/microbiology , Child , False Positive Reactions , Female , Humans , Lung Diseases, Fungal/complications , Lung Diseases, Fungal/microbiology , Male , Middle Aged , Predictive Value of Tests , Prospective Studies
16.
Mycopathologia ; 141(2): 65-8, 1998.
Article in English | MEDLINE | ID: mdl-9750336

ABSTRACT

The objective of this study was to characterize the epidemiology of candidemia in cancer patients in the city of Rio de Janeiro, Brazil. An 18-month survey of fungemia in patients with cancer was undertaken in three Hospitals in Rio de Janeiro. Forty-three episodes of candidemia were identified in 43 patients, 43 of which were episodes of candidemia; in ten case the strains were not available for further identification of species and were excluded from this analysis. The overall distribution of fungi causing fungemia was: Candida albicans (5), Candida tropicalis (16), Candida parapsilosis (6), Candida guilliermondii (4), Candida lusitaniae (1) and Candida stellatoidea (1). Antifungal prophylaxis had been administered before the episode of fungemia in only six patients (18.2%): oral itraconazole in three patients and oral nistatin, low dose intravenous amphotericin B and oral fluconazole in one patient each. There was no difference in the presence of risk factors, clinical characteristics or in the outcome between albicans and non-albicans species, nor between Candida tropicalis and other non-albicans species. There was a clear predominance of non-albicans species, regardless of the underlying disease, antifungal prophylaxis or the presence of neutropenia.


Subject(s)
Candida/isolation & purification , Candidiasis/epidemiology , Fungemia/epidemiology , Neoplasms/complications , Brazil/epidemiology , Candidiasis/complications , Candidiasis/microbiology , Data Collection , Female , Fungemia/complications , Fungemia/microbiology , Humans , Male , Prospective Studies
17.
Oncol Rep ; 5(5): 1205-9, 1998.
Article in English | MEDLINE | ID: mdl-9683836

ABSTRACT

A prospective randomized trial was performed to compare teicoplanin to vancomycin as part of the empirical antibiotic therapy of febrile neutropenic cancer patients. Fifty-three patients were randomized to receive ceftazidime (100 mg/kg daily every 8 h), amikacin (15 mg/kg daily every 8 h) and teicoplanin (6 mg/kg once a day) and 53 other patients received ceftazidime, amikacin (same dosages) and vancomycin (30 mg/kg/day every 6 h). In 99 evaluable episodes, the success rates were 54% for patients receiving teicoplanin and 52% for patients receiving vancomycin (p=0.76, 95% CI-18-23). The response rates were similar for patients with unexplained fever and for patients with documented infections. There were no differences in renal toxicity or cutaneous side effects between the two groups. The overall death rate was 18.9%, with 10 deaths in each group. The most important factor associated with death was the diagnosis of a fungal infection (p=0.001). Teicoplanin seems to be well tolerated and as effective as vancomycin in the empirical antibiotic therapy of fever in neutropenic cancer patients.


Subject(s)
Amikacin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Bacterial Infections/drug therapy , Ceftazidime/therapeutic use , Drug Therapy, Combination/therapeutic use , Fever , Leukemia/complications , Lymphoma/complications , Neutropenia , Teicoplanin/therapeutic use , Vancomycin/therapeutic use , Adolescent , Adult , Aged , Bacterial Infections/complications , Bone Marrow Transplantation , Child , Female , Gram-Negative Bacterial Infections/complications , Gram-Negative Bacterial Infections/drug therapy , Humans , Leukemia/therapy , Lymphoma/therapy , Male , Middle Aged , Prospective Studies
18.
Clin Infect Dis ; 27(1): 107-11, 1998 Jul.
Article in English | MEDLINE | ID: mdl-9675463

ABSTRACT

In order to identify prognostic factors for death among cancer patients with fungemia, an 18-month survey of fungemia in patients with cancer was undertaken in three hospitals in Rio de Janeiro. For the assessment of risk factors for death, the following variables were analyzed: age; gender; underlying cancer; last treatment for the underlying disease; previous surgery; use of antibiotics, antifungal agents, steroids, or total parenteral nutrition; use of a central venous catheter; chemotherapy; radiotherapy; presence and duration of neutropenia; etiologic agent of the fungemia; treatment of the fungemia; clinical manifestations; and performance status (Karnofsky score) on the day of the positive blood culture. In multivariate analysis, the variables associated with an increased risk for death were older age, persistent neutropenia, and low performance status. Identifying risk factors for death may help to define a group-risk patients for whom new therapeutic options should be tried.


Subject(s)
Fungemia/complications , Fungemia/mortality , Neoplasms/complications , Neoplasms/mortality , Adult , Aged , Female , Humans , Male , Middle Aged , Multivariate Analysis , Prognosis , Risk Factors , Statistics, Nonparametric , Survival Analysis
20.
Leuk Lymphoma ; 26(1-2): 171-6, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9250802

ABSTRACT

The role of bone marrow biopsy in the staging of Hodgkin's disease is undergoing reevaluation. We have studied the relationship of clinical factors to the presence of bone marrow involvement in 130 previously untreated patients with Hodgkin's disease. The presence of fever, spleen enlargement, anemia, leukopenia, poor performance status and poor histologic subgroups were positively correlated with the presence of bone marrow involvement in the univariate analysis. In the multivariate analysis, only fever, spleen involvement, leukopenia and poor histologic subgroups were significant. The predictive value of the absence of fever in regard to the absence of bone marrow involvement was 98%. The likelihood of bone marrow involvement in the absence of all four significant factors was only 0.05%. Patients without these clinical factors should probably not be submitted to a bone marrow biopsy as part of the staging procedures performed in Hodgkin's disease.


Subject(s)
Bone Marrow Diseases/diagnosis , Hodgkin Disease/complications , Adolescent , Adult , Aged , Bone Marrow Diseases/etiology , Brazil , Female , Humans , Leukocyte Count , Male , Middle Aged , Multivariate Analysis , Predictive Value of Tests , Retrospective Studies , United States , Urban Health
SELECTION OF CITATIONS
SEARCH DETAIL
...